Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominick J Angiolillo

Showing results (211-220 of 760) with videos related to

Pageof 76
Sort By:
Journal of Thrombosis and Thrombolysis|December 26, 2013
Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studiesDominick J Angiolillo, Catherine Datto, Shane Raines, et al.
Progress in Cardiovascular Diseases|January 2, 2018
Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet TherapyJae Youn Moon, Francesco Franchi, Fabiana Rollini, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|June 2, 2017
Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to BedsideJae Youn Moon, Francesco Franchi, Fabiana Rollini, et al.
Thrombosis and Haemostasis|June 29, 2020
Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the EvidenceJeffrey Ian Weitz, Dominick J Angiolillo, Tobias Geisler, et al.
European Heart Journal|September 21, 2022
The search for optimal antithrombotic therapy in transcatheter aortic valve implantation: facts and uncertaintiesJurrien Ten Berg, Bianca Rocca, Dominick J Angiolillo, et al.
Therapeutic Advances in Cardiovascular Disease|July 3, 2013
Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practiceAna Muñiz-Lozano, Fabiana Rollini, Francesco Franchi, et al.
Journal of the American College of Cardiology|September 5, 2020
Reply: P2Y<sub>12</sub> Inhibitor-Based Monotherapy: Optimal Duration and Ideal AgentDominick J Angiolillo, Usman Baber, George D Dangas, et al.
Expert Review of Hematology|November 2, 2017
The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shiftsJae Youn Moon, Francesco Franchi, Fabiana Rollini, et al.
Journal of Thrombosis and Thrombolysis|May 25, 2025
Antiplatelet therapy following conservatively managed spontaneous coronary artery dissectionMadeline K Mahowald, Luis Ortega-Paz, Claudio Laudani, et al.
British Journal of Clinical Pharmacology|September 13, 2011
Antiplatelet therapy: thrombin receptor antagonistsAntonio Tello-Montoliu, Salvatore D Tomasello, Masafumi Ueno, et al.
Pageof 76

Showing results (211-220 of 760) with videos related to

Sort By:
Pageof 76
Journal of Thrombosis and Thrombolysis|December 26, 2013
Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studiesDominick J Angiolillo, Catherine Datto, Shane Raines, et al.
Progress in Cardiovascular Diseases|January 2, 2018
Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet TherapyJae Youn Moon, Francesco Franchi, Fabiana Rollini, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|June 2, 2017
Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to BedsideJae Youn Moon, Francesco Franchi, Fabiana Rollini, et al.
Thrombosis and Haemostasis|June 29, 2020
Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the EvidenceJeffrey Ian Weitz, Dominick J Angiolillo, Tobias Geisler, et al.
European Heart Journal|September 21, 2022
The search for optimal antithrombotic therapy in transcatheter aortic valve implantation: facts and uncertaintiesJurrien Ten Berg, Bianca Rocca, Dominick J Angiolillo, et al.
Therapeutic Advances in Cardiovascular Disease|July 3, 2013
Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practiceAna Muñiz-Lozano, Fabiana Rollini, Francesco Franchi, et al.
Journal of the American College of Cardiology|September 5, 2020
Reply: P2Y<sub>12</sub> Inhibitor-Based Monotherapy: Optimal Duration and Ideal AgentDominick J Angiolillo, Usman Baber, George D Dangas, et al.
Expert Review of Hematology|November 2, 2017
The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shiftsJae Youn Moon, Francesco Franchi, Fabiana Rollini, et al.
Journal of Thrombosis and Thrombolysis|May 25, 2025
Antiplatelet therapy following conservatively managed spontaneous coronary artery dissectionMadeline K Mahowald, Luis Ortega-Paz, Claudio Laudani, et al.
British Journal of Clinical Pharmacology|September 13, 2011
Antiplatelet therapy: thrombin receptor antagonistsAntonio Tello-Montoliu, Salvatore D Tomasello, Masafumi Ueno, et al.
Pageof 76